Top Story

WOSCOPS: 20-year follow-up demonstrates clinical benefit of statins in men

November 26, 2014

CHICAGO — At 20 years, men assigned statin therapy during the 5-year West of Scotland Coronary Prevention Study had lower rates for mortality and CV events compared with men assigned placebo, regardless of whether they continued taking statins, according to findings presented at the American Heart Association Scientific Sessions.

From 1989 to 1995, researchers randomly assigned 6,595 men aged 45 to 64 years to pravastatin 40 mg/day or placebo. For the original West of Scotland Coronary Prevention Study (WOSCOPS), they remained randomly assigned for 5 years. After the initial 5-year period, in which the pravastatin group had LDL lowered by approximately 20% more than the placebo group, participants continued to be followed, but their general practitioners decided whether to initiate or continue statin therapy. An interim analysis had found that after the original trial, statin usage was equal in both treatment arms, with 31% of men in both groups using statins.

Doug Mann Meeting News Coverage

AUGMENT-HF: Novel implantable device safe, effective in patients with advanced HF

November 26, 2014
CHICAGO — A novel implantable device was administered safely and associated with clinical benefit in patients with advanced HF, according to phase 2 trial data…
thumbnail for video 3909640743001 Meeting News CoverageVideo

VIDEO: Increased infective endocarditis incidence in England may merit re-evaluation of treatment guidelines

November 25, 2014
CHICAGO — In this video, John G. Harold, MD, cardiologist at the Cedars-Sinai Heart Institute, discusses data presented at the American Heart Association…
In the Journals

PROTECTION AMI: Cardiac troponin I levels predicted STEMI outcomes

November 25, 2014
In a new analysis, researchers reported an independent association between measurement of cardiac troponin I levels after primary PCI for STEMI and clinical outcomes and…
In the Journals

Beta-blockers lowered all-cause mortality in patients with HFpEF

November 25, 2014
Patients with HF with preserved ejection fraction who received treatment with beta-blockers had lower rates of all-cause mortality, according to new study…
More News Headlines »
Controversial Issues and Challenging Cases

Controversial Issues and Challenging Cases in the New Frontier of Obesity Online Activity

This activity is supported by an educational grant from Eisai Inc.

Obesity has become a world-wide issue of utmost importance as its incidence and prevalence are associated with dramatic…
More »
Meeting News Coverage Video
thumbnail for video 3907832195001

Anna Axelsson, MD: Results from INHERIT do not 'close the door' on losartan

November 24, 2014
CHICAGO — While results from the INHERIT trial indicate that losartan had no effect on left ventricular mass or…
More »
Risk Management in the Cardiovascular Disease Arena

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

This activity is supported by an educational grant from Genentech.

Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM)…
More »